Core Points - Diagnos Inc. intends to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [4] - The company's technology aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]

Brossard, Quebec--(Newsfile Corp. - October 15, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce it will be presenting at the Centurion One Capital 3rd Annual Bahamas Summit, a two-day invitation only event taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, i ...

Group 1 - The core announcement is about Diagnos Inc. conducting a non-brokered private placement of 10 units at a price of $10,000 per unit, aiming for gross proceeds of $100,000 [1][2] - Each unit consists of an unsecured convertible debenture with a 12-month term and an annual interest rate of 10%, which can be converted into common shares at a price of $0.28 per share [1][2] - Additionally, each warrant allows the holder to purchase one share at a price of $0.40 per share during the term [2] Group 2 - The proceeds from the private placement will primarily fund product development and commercialization of AI-based screening services, along with general and administrative expenses [2] - A director of the corporation has committed to subscribe for all units in the private placement [2] - All securities issued will be subject to a 4-month statutory hold period and require approval from the TSX Venture Exchange [3] Group 3 - Diagnos Inc. is focused on early detection of critical eye-related health issues using advanced AI technology to enhance diagnostic accuracy and improve patient outcomes globally [4]

Core Points - Diagnos Inc. intends to extend the exercise period of 650,000 stock warrants to August 5, 2026, from the original expiry date of September 22, 2025 [1][2] - A correction was made regarding the expiry date of 1,414,286 warrants, which will also be extended to August 5, 2026, instead of February 27, 2029 [3] - The exercise price of the warrants remains unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos Inc. is a Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [5] - The company aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [5]

Core Points - Diagnos Inc. intends to extend the exercise period of 1,414,286 stock warrants from August 27, 2025, to February 27, 2029 [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share [2] - An insider holds 357,143 of the warrants, and the amendment is exempt from certain requirements under Multilateral Instrument 61-101 due to the fair market value being below 25% of the corporation's market capitalization [3] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [5] - The company's goal is to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [5]

BROSSARD, Quebec, July 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian leader in artificial intelligence (AI) for the early detection of retinal and systemic diseases, is proud to announce that it has formally submitted a Pre-Submission (Q-sub) to the U.S. Food and Drug Administration (FDA) for its flagship CARA System. This filing marks the first strategic step toward regulatory clearance and commercial deployment in the U.S ...

BROSSARD, Quebec, June 25, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Dr. Barry A. Ginsberg, O.D. has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and M ...

Core Insights - Diagnos Inc. has appointed Mr. Ed Weiner to its Advisory Board to enhance its insights into the US optical market [1][2] - The company aims to leverage AI technology for early detection of critical eye-related health issues, targeting a growing market of routine and medical eye exams in the US [3][4] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on early detection of critical eye-related health problems using Artificial Intelligence [4] - The company has developed an AI platform to analyze retina images, which are collected from thousands of optometrists globally [3] Market Potential - In 2020, the US conducted approximately 111 million routine eye exams and 60 million medical eye exams, indicating a significant market opportunity for Diagnos [3] - The recent establishment of a US office in south Florida is aimed at supporting the company's prospects and clients in the US market [3]

Core Insights - Diagnos Inc. has engaged Allele Capital Partners for capital markets advisory and social media services to enhance its business strategy and shareholder value [1][3]. Group 1: Engagement Details - The agreement with Allele includes a monthly compensation of US$7,500 for the period from May 22, 2025, to August 22, 2025, with the option for DIAGNOS to terminate the agreement with 30 days' notice [2]. - After the initial trial period, the agreement can be renewed for an additional nine months at the same compensation rate, subject to written confirmation from DIAGNOS [2]. Group 2: Company Overview - DIAGNOS is focused on the early detection of critical eye-related health issues using advanced AI technology to improve diagnostic accuracy and patient outcomes globally [5]. - The company aims to provide healthcare clinicians with enhanced information to streamline workflows and optimize capital needs [3].

BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application. As part of its ongoing ISO 27001 certification process, DIAGNOS is pleased to announce that its CARA Sy ...